newsfilter
← Latest News
GlobeNewswire·

CinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldosterone Synthase Inhibitor Baxdrostat in Treatment-Resistant Hypertension

Clinically significant and dose-dependent reduction in blood pressure with baxdrostat Highly selective mechanism of action with no meaningful impact on cortisol supports first-in-class potential Potential treatment for